Show simple item record

dc.contributor.authorSimpson, Peter
dc.contributor.authorDesai, N.
dc.contributor.authorCasari, I.
dc.contributor.authorMassi, Massimiliano
dc.contributor.authorFalasca, Marco
dc.identifier.citationSimpson, P. and Desai, N. and Casari, I. and Massi, M. and Falasca, M. 2019. Metal-based antitumor compounds: beyond cisplatin. Future Medicinal Chemistry. 11 (2): pp. 119-135.

Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.

dc.titleMetal-based antitumor compounds: beyond cisplatin
dc.typeJournal Article
dcterms.source.titleFuture Medicinal Chemistry
curtin.departmentNanochemistry Research Institute
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record